Summary
PODD Chart
Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjamin - Executive VP, Chief Product & Customer Experience Officer June Lazaroff - Senior Director of Investor Relations Conference Call Participants Danielle Joy Antalffy - UBS Investment Bank, Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Issie Kirby - Redburn (Europe) Limited, Research Division Jayson Tyler Bedford - Raymond James & Associates, Inc., Research Division Jeffrey D.
Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.
Insulet Corporation Dividends
Insulet Corporation Earnings
| 6 Nov 2025 (In 3 months) Date | | 1.12 Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 30 Oct 2025 (In 2 months) Date | | 1.1 Cons. EPS | - EPS |
| 14 Aug 2025 (In 6 days) Date | | 0.93 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 0.92 Cons. EPS | - EPS |
| 6 Nov 2025 (In 3 months) Date | | 1.12 Cons. EPS | - EPS |
| 5 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 30 Oct 2025 (In 2 months) Date | | 1.1 Cons. EPS | - EPS |
| 14 Aug 2025 (In 6 days) Date | | 0.93 Cons. EPS | - EPS |
| 7 Aug 2025 Date | | 0.92 Cons. EPS | - EPS |
Insulet Corporation (PODD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Insulet Corporation ever had a stock split?
Insulet Corporation Profile
| Medical - Devices Industry | Healthcare Sector | Ashley A. McEvoy CEO | NASDAQ (NGS) Exchange | 45784P101 Cusip |
| US Country | 3,900 Employees | - Last Dividend | - Last Split | 15 May 2007 IPO Date |
Overview
Insulet Corporation is a pioneering healthcare company that specializes in the development, manufacturing, and sale of innovative insulin delivery systems intended primarily for individuals with insulin-dependent diabetes. Founded in the year 2000 and with its headquarters located in Acton, Massachusetts, Insulet Corporation aims to improve the quality of life for people living with diabetes through its cutting-edge products. The company markets its solutions across a broad geographic spectrum including the United States, Canada, Europe, the Middle East, Australia, and other international markets, leveraging both direct sales and a network of independent distributors and pharmacy channels.
Products and Services
- Omnipod 5 Automated Insulin Delivery System (Omnipod 5)
The Omnipod 5 stands out as a flagship offering from Insulet Corporation, showcasing a proprietary Automated Insulin Delivery (AID) algorithm built into the Pod. This system is designed to seamlessly integrate with a third-party continuous glucose monitor (CGM), with the aim of obtaining glucose readings via wireless Bluetooth communication. This integration facilitates a dynamic adjustment of insulin delivery, aiming to maintain glucose levels within the target range, hence offering a sophisticated solution to insulin management.
- Omnipod DASH
Omnipod DASH elevates the convenience of insulin delivery systems by featuring a Bluetooth-enabled Pod, which is managed through a user-friendly Personal Diabetes Manager (PDM). The PDM, resembling a smartphone in its design, comes equipped with a color touch screen user interface. This system provides users a blend of advanced technology and ease of use, making daily diabetes management more manageable and less intrusive.
- Omnipod GO
The Omnipod GO system introduces a standalone, wearable insulin delivery solution that administers a fixed rate of continuous rapid-acting insulin over a duration of 72 hours. This system is tailored for those seeking simplicity and effectiveness in their insulin therapy, catering especially to individuals who prefer a straightforward approach to diabetes management without the need for frequent adjustments.
Contact Information
